ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

VRAX Virax Biolabs Group Ltd

0.61
-0.039 (-6.01%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Virax Biolabs Group Ltd VRAX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.039 -6.01% 0.61 18:58:14
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.66 0.61 0.6681 0.61 0.649
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202407:00PRNUSVirax Biolabs Launches Portfolio of Immune Profiling..
16/4/202406:30PRNUSVirax Biolabs to Participate at ESCMID Global 2024
15/3/202415:30PRNUSVirax Biolabs Announces Receipt of NASDAQ Notification..
22/1/202416:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202416:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/1/202406:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202306:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202306:30PRNUSVirax Biolabs Forges Strategic Research Collaboration with..
20/12/202315:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/12/202315:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202315:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/12/202306:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202306:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
17/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
14/12/202306:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202306:30PRNUSVirax Biolabs Group Limited Announces 1-for-10 Share..
08/12/202305:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202315:06EDGAR2Form F-3 - Registration statement by foreign private issuers
08/11/202315:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202315:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202306:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202306:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202306:30PRNUSVirax Biolabs Group Announces Early-Access Program Launch of..
01/9/202306:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202306:30PRNUSVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief..
03/8/202307:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202306:30PRNUSNasdaq Approves 180-Day Extension for Virax Biolabs Group to..
18/7/202306:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202306:30PRNUSVirax Biolabs Group Continues Growth and Expansion with the..
14/6/202306:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
04/5/202306:30PRNUSVirax Biolabs Group Announces Establishment of Regional..

Su Consulta Reciente

Delayed Upgrade Clock